- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Open-label Study Evaluating the Long term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 2 Years and Older
This study is looking at the long-term safety and effectiveness of a new three-in-one medicine called Kaftrio (also known as Elexacaftor/Tezacaftor/Ivacaftor) for people aged 2 and older with Cystic Fibrosis. Researchers want to see how well it works and if it has any side effects over time.
For: Cystic FibrosisGermany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Open-label Study Evaluating the Pharmacokinetics, Safety, and Tolerability of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects 12 to Less Than 24 Months of Age
This study is testing a new combination medicine for babies and toddlers aged 12 to 24 months with Cystic Fibrosis. Researchers want to ensure the medicine is safe and well-tolerated, and how it moves through the body.
For: Cystic FibrosisGermany · Netherlands · Denmark